

# Ciclesonid

## Pharmakokinetische und pharmakodynamische Eigenschaften

Hartmut Derendorf, Melanie Hübner, Gainesville (Florida), Bernd Drewelow, Rostock, Uwe Fuhr, Köln, Christoph H. Gleiter, Tübingen, Björn Lemmer, Gerd Mikus, Heidelberg, Ivar Roots, Berlin, Albrecht Ziegler, Kiel und Dieter Ukena, Bremen

### Literatur

- Tashkin D. The role of small airway inflammation in asthma. *Allergy Asthma Proc* 2002;23:233–42.
- Leung D, Bloom J. Update on glucocorticoid action and resistance. *J Allergy Clin Immunol* 2003;111:1–20.
- Kroegel C, et al. Inhalierbare Glucocorticoide der dritten Generation. *Arzneimitteltherapie* 2006;24:73–83.
- Howarth P. Why particle size should affect clinical response to inhaled therapy. *J Aerosol Med* 2001;14(Suppl 1):S27–34.
- Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. *Thorax* 2002;57:880–4.
- Apter AJ. Clinical advances in adult asthma. *J Allergy Clin Immunol* 2003;111(Suppl 3):S780–4.
- Toogood J. Side effects of inhaled corticosteroids. *J Allergy Clin Immunol* 1998;102:705–13.
- Derendorf H, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. *J Allergy Clin Immunol* 1998;101:440–6.
- Lemmer B. Bronchospasmolytika und Antiasthmatica. In: Schwabe U (Hrsg.). *Arzneiverordnungs-Report 2005*. Berlin: Springer, 2006.
- Kelly H. Comparative potency and clinical efficacy of inhaled corticosteroids. *Respir Care Clin North Am* 1999;5:537–53.
- Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. *Resp Med* 1997;91(Suppl A):22–8.
- Boobis A. Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. *Respir Med* 1998;92(Suppl B):2–6.
- Valotis A, Hogger P. Significant receptor affinities of metabolites and a degradation product of mometasone furoate. *Respir Res* 2004;5:7.
- Valotis A, et al. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. *J Pharm Sci* 2004;93:1337–50.
- Hochhaus G, et al. Glucocorticoid activity and structure activity relationships in a series of some novel 17 alpha-ether-substituted steroids: influence of 17 alpha-substituents. *Drug Des Discov* 1991;8:117–25.
- Hochhaus G, et al. Assessment of glucocorticoid lung targeting by ex vivo receptor binding studies in rats. *Pharm Res* 1995;12:134–7.
- Hochhaus G, et al. Identification of glucocorticoid receptors in normal and neoplastic adult human lung. *Res Exp Med (Berl)* 1983;182:71–8.
- Dietzel K, Engelstatter R, Keller A. Ciclesonide: an on-site-activated steroid. In: Hansel T, Barnes P (eds.). *New drugs for asthma, allergy and COPD*. Basel: Karger, 2001:91–3.
- Mollmann H, et al. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as diskus or turbobalder dry-powder inhalers to healthy subjects. *J Clin Pharmacol* 2001;41:1329–38.
- Bethke T, et al. High lung deposition of ciclesonide in 2D and 3D imaging. *European Respiratory Society Annual Meeting* 2002. Stockholm, Sweden, 2002.
- Thorsson L, Edsbacker S, Conradson T-B. Lung deposition of budesonide from turbobalder is twice that from a pressurised metered dose inhaler P-MDI. *Eur Respir J* 1994;7:1839–44.
- Ryrfeldt A, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. *Eur J Respir Dis* 1982;63:86–95.
- Daley-Yates P, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. *Br J Clin Pharmacol* 2001;51:400–9.
- Thorsson L, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. *Br J Clin Pharmacol* 1997;43:155–61.
- Mollmann H, et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. *Eur J Clin Pharmacol* 1998;53:459–67.
- Nave R, et al. Pharmacokinetics of 14C-ciclesonide after oral and intravenous administration in healthy subjects. *European Respiratory Society Annual Congress* 2002. Stockholm, Sweden, 2002.
- Affrime M, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. *J Clin Pharmacol* 2000;40:1227–36.
- Derendorf H, et al. Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology. *J Clin Pharmacol* 2002;42:383–7.
- Crim C, Pierre L, Daley-Yates P. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. *Clin Ther* 2001;23:1339–54.
- Brocklebank D, Wright J, Cates C. National Health Technology Assessment Inhaler Review Group. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. *Brit Med J* 2001;323:1–7.
- Lipworth B, Jackson C. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. *Drug Safety* 2000;23:11–33.
- Leach C, Davidson P, Boudreau R. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. *Eur Respir J* 1998;12:1346–53.
- Rowland M, Tozer T. *Clinical Pharmacokinetics: Concepts and Applications*. Third ed. Philadelphia, PA: Williams & Wilkins, 1995.
- Mackie A et al. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. *Br J Clin Pharmacol* 1996;41:539–42.
- Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in the human lung and liver as determined by use of precision-cut tissue slices. *American Thoracic Society 99th International Conference* 2003. Seattle, WA, 2003.
- Nave R, et al. Formation of fatty acid conjugates of ciclesonide-active principle in the rat lung after 4-week inhalation of ciclesonide. *American Thoracic Society 99th International Conference* 2003. Seattle, Washington, 2003.
- Nave R, et al. Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration

---

Prof. Dr. Hartmut Derendorf, Melanie Hübner, Department of Pharmaceutics, University of Florida, P.O. Box 100494, Gainesville, FL 32610-0494, USA, E-Mail: hartmut@ufl.edu  
 Prof. Dr. Bernd Drewelow, Institut für Klinische Pharmakologie, Universität Rostock, Schillingallee 70, 18055 Rostock, E-Mail: bernd.drewelow@med.uni-rostock.de  
 Prof. Dr. Uwe Fuhr, Institut für Pharmakologie der Universität zu Köln, Gleueler Straße 24, 50931 Köln, E-Mail: uwe.fuhr@uk-koeln.de  
 Prof. Dr. Christoph H. Gleiter, Abt. Klinische Pharmakologie, Institut für Pharmakologie und Toxikologie, Otfried Müller-Str. 45, 72076 Tübingen, E-Mail: christoph.gleiter@med.uni-tuebingen.de  
 Prof. Dr. Björn Lemmer, Institut für Pharmakologie und Toxikologie, Universität Heidelberg, Maybachstr. 14, 68169 Mannheim, E-Mail: bjoern.lemmer@pharmatox.uni-heidelberg.de  
 Prof. Dr. Gerd Mikus, Klinische Pharmakologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, E-Mail: gerd.mikus@med.uni-heidelberg.de  
 Prof. Dr. Ivar Roots, Institut für Klinische Pharmakologie, Freie Universität Berlin, Luisenstr. 6-8, 10117 Berlin, E-Mail: ivar.roots@charite.de  
 Prof. Dr. Albrecht Ziegler, Institut für Pharmakologie, Universität Kiel, Hospitalstrasse 4, 24105 Kiel, E-Mail: aziegler@pharmakologie.uni-kiel.de  
 Prof. Dr. Dieter Ukena, Klinik für Pneumologie, Klinikum Bremen-Ost, Züricher Str. 40, 28325 Bremen, E-Mail: Dieter.Ukena@klinikum-bremen-ost.de

- in healthy subjects. European Respiratory Society Annual Congress 2002. Stockholm, Sweden, 2002.
38. Rohatagi S, et al. PK/PD of inhaled corticosteroids: the risk/benefit of inhaled ciclesonide. The 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology, Denver, CO, 2003.
  39. Edsbacker S, Brattsand R. Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. *Ann Allergy Asthma Immunol* 2002;88:609–16.
  40. Tunek A, Sjodin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. *Drug Metab Depos* 1997;25:1311–7.
  41. Miller-Larsson A, et al. Reversible fatty acid conjugation of budesonide: novel mechanism for prolonged retention of topically applied steroid in airway tissue. *Drug Metab Depos* 1998;26:623–30.
  42. Szeffler S. Pharmacokinetics of intranasal corticosteroids. *J Allergy Clin Immunol* 2001;108(Suppl 1):S26–31.
  43. Rohatagi S, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. *J Clin Pharmacol* 2003;43:365–78.
  44. Meibohm B, et al. A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. *J Pharmacokinet Biopharm* 1999;27:127–47.
  45. Lipworth B. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. *Arch Intern Med* 1999;159:941–55.
  46. Affrime M, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. *Chest* 2000;118:1538–46.
  47. Weinbrenner A, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. *J Clin Endocrinol Metab* 2002;87:2160–3.
  48. Derom E, et al. Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients. The European Respiratory Society Annual Congress. Berlin, 2001.
  49. Pauwels R, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and PC20 for adenosine in asthma patients [abstract]. American Thoracic Society 98th International Conference, Atlanta, GA, 2002.
  50. Szeffler S, et al. High doses of the novel inhaled corticosteroid ciclesonide have no effect on HPA-axis function in patients with moderate-to-severe persistent asthma. *J Allergy Clin Immunol* 2003;111:Abstract 590.
  51. Nave R, Zech K, Bethke T. Oropharyngeal deposition of inhaled ciclesonide and budesonide in healthy subjects. The 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology, Denver, CO, 2003.
  52. Richter K, et al. Oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in asthmatics. American Thoracic Society 98th International Conference, Atlanta, GA, 2002.
  53. Stoeck M, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. *J Pharmacol Exp Ther* 2004;309:249–58.
  54. Leung SY, et al. Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features. *J Allergy Clin Immunol* 2005;115:989–96.
  55. Derom E, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'-monophosphate in asthmatic patients. *Pulm Pharmacol Ther* 2005;18:328–36.
  56. Lee DK, et al. Effects of hydrofluoroalkane formulations of ciclesonide 400 µg once daily vs fluticasone 250 µg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. *Br J Clin Pharmacol* 2004;58:26–33.
  57. Ukena D. Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomized 12-week study. *Eur Respir J* 2003;22(Suppl 45):411s.
  58. Buhl R. Titel?? *Am J Respir Crit Care* 2004;169:A91.
  59. Chapman KR, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. *Allergy* 2005;60:330–7.
  60. Christie P. Ciclesonide: a novel inhaled corticosteroid for asthma. *Drugs Today (Barc)* 2004;40:569–76.
  61. Reynolds NA, Scott LJ. Ciclesonide. *Drugs* 2004;64:511–9; discussion 520–1.
  62. Dickens G, et al. Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. *Ann Allergy Asthma Immunol* 2000;84:528–32.
  63. Peterson L. Titel?? *Trends Med* 2002;Vol. No.?:5–6.